KRMD vs SMIN.L
KRMD: Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases, while generating services revenue from pharma partnerships in novel subcutaneous drug development. SMIN.L: Smiths Group is a global industrial technology leader delivering advanced solutions for the threat detection, energy, aerospace, and medical sectors.
Side-by-side fundamentals
| Metric | KRMD | SMIN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $3.21 | £25.83 | |
| Market cap as of 2026-08-24 | $148M | $10.4B | |
| Net margin as of 2026-08-24 | -4.0% | n/a | |
| Gross margin as of 2026-08-24 | +62.4% | n/a | |
| Operating margin as of 2026-08-24 | -3.7% | n/a | |
| ROE as of 2026-08-24 | -10.6% | n/a | |
| ROA as of 2026-08-24 | -6.5% | n/a | |
| Debt / equity as of 2026-08-24 | 0.01 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +22.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +13.8% | n/a | |
| Beta as of 2026-08-24 | 0.36 | n/a | |
| 1-year return as of 2026-08-21 close | -21.9% | +9.4% | SMIN.L higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.